Hanall Biopharma Co.,Ltd (009420.KS)
KRW 32650.0
(-6.18%)
KRW 32650.0
(-6.18%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.29 Billion KRW | -1.52% |
| 2022 | 1.31 Billion KRW | -1.85% |
| 2021 | 1.33 Billion KRW | 142.08% |
| 2020 | 551.51 Million KRW | -2.93% |
| 2019 | 568.18 Million KRW | 0.0% |
| 2018 | - KRW | 0.0% |
| 2017 | - KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | -100.0% |
| 2014 | 20.19 Billion KRW | 16.86% |
| 2013 | 17.28 Billion KRW | -35.21% |
| 2012 | 26.67 Billion KRW | -25.49% |
| 2011 | 35.79 Billion KRW | -30.72% |
| 2010 | 51.67 Billion KRW | 0.74% |
| 2009 | 51.28 Billion KRW | 22.08% |
| 2008 | 42.01 Billion KRW | 61.31% |
| 2007 | 26.04 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 1.15 Billion KRW | -14.77% |
| 2024 Q1 | 1.35 Billion KRW | 4.7% |
| 2023 Q3 | 1.11 Billion KRW | -11.81% |
| 2023 Q4 | 1.29 Billion KRW | 15.86% |
| 2023 FY | 1.29 Billion KRW | -1.52% |
| 2023 Q1 | 1.28 Billion KRW | -1.78% |
| 2023 Q2 | 1.26 Billion KRW | -1.87% |
| 2022 FY | 1.31 Billion KRW | -1.85% |
| 2022 Q2 | 1.24 Billion KRW | 0.76% |
| 2022 Q1 | 1.23 Billion KRW | -7.4% |
| 2022 Q4 | 1.31 Billion KRW | 20.41% |
| 2022 Q3 | 1.08 Billion KRW | -12.64% |
| 2021 Q2 | 1.68 Billion KRW | 248.35% |
| 2021 FY | 1.33 Billion KRW | 142.08% |
| 2021 Q1 | 482.57 Million KRW | -12.5% |
| 2021 Q3 | 1.5 Billion KRW | -10.7% |
| 2021 Q4 | 1.33 Billion KRW | -11.06% |
| 2020 FY | 551.51 Million KRW | -2.93% |
| 2020 Q4 | 551.51 Million KRW | -1.39% |
| 2020 Q1 | 608.08 Million KRW | 7.02% |
| 2020 Q3 | 559.26 Million KRW | -19.48% |
| 2020 Q2 | 694.53 Million KRW | 14.22% |
| 2019 Q4 | 568.18 Million KRW | 12.51% |
| 2019 FY | 568.18 Million KRW | 0.0% |
| 2019 Q1 | 613.69 Million KRW | 0.0% |
| 2019 Q2 | 591.67 Million KRW | -3.59% |
| 2019 Q3 | 505.01 Million KRW | -14.65% |
| 2018 Q4 | - KRW | 0.0% |
| 2018 Q1 | - KRW | 0.0% |
| 2018 FY | - KRW | 0.0% |
| 2018 Q2 | - KRW | 0.0% |
| 2018 Q3 | - KRW | 0.0% |
| 2017 Q2 | - KRW | 0.0% |
| 2017 FY | - KRW | 0.0% |
| 2017 Q4 | - KRW | 0.0% |
| 2017 Q3 | - KRW | 0.0% |
| 2017 Q1 | - KRW | 0.0% |
| 2016 Q3 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2015 Q1 | 20.2 Billion KRW | 0.03% |
| 2015 FY | - KRW | -100.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 Q3 | - KRW | -100.0% |
| 2015 Q2 | 17.86 Billion KRW | -11.56% |
| 2014 Q1 | 17.28 Billion KRW | 0.0% |
| 2014 FY | 20.19 Billion KRW | 16.86% |
| 2014 Q2 | 17.84 Billion KRW | 3.28% |
| 2014 Q4 | 20.19 Billion KRW | 7.89% |
| 2014 Q3 | 18.71 Billion KRW | 4.88% |
| 2013 Q4 | 17.28 Billion KRW | 0.75% |
| 2013 FY | 17.28 Billion KRW | -35.21% |
| 2013 Q1 | 25.21 Billion KRW | -5.46% |
| 2013 Q2 | 25.06 Billion KRW | -0.6% |
| 2013 Q3 | 17.15 Billion KRW | -31.57% |
| 2012 FY | 26.67 Billion KRW | -25.49% |
| 2012 Q4 | 26.67 Billion KRW | 0.0% |
| 2012 Q1 | 32.42 Billion KRW | 0.0% |
| 2011 FY | 35.79 Billion KRW | -30.72% |
| 2011 Q3 | 32.34 Billion KRW | -23.96% |
| 2011 Q1 | 50.7 Billion KRW | -1.87% |
| 2011 Q2 | 42.54 Billion KRW | -16.09% |
| 2010 Q3 | 52.45 Billion KRW | 2.05% |
| 2010 Q1 | 52.2 Billion KRW | 1.79% |
| 2010 Q2 | 51.4 Billion KRW | -1.54% |
| 2010 FY | 51.67 Billion KRW | 0.74% |
| 2010 Q4 | 51.67 Billion KRW | -1.5% |
| 2009 FY | 51.28 Billion KRW | 22.08% |
| 2009 Q4 | 51.28 Billion KRW | 3.18% |
| 2009 Q3 | 49.71 Billion KRW | 17.83% |
| 2009 Q2 | 42.19 Billion KRW | 3.87% |
| 2009 Q1 | 40.61 Billion KRW | -3.32% |
| 2008 Q2 | 25.43 Billion KRW | -0.31% |
| 2008 Q1 | 25.51 Billion KRW | -2.04% |
| 2008 Q3 | 25.35 Billion KRW | -0.32% |
| 2008 Q4 | 42.01 Billion KRW | 65.71% |
| 2008 FY | 42.01 Billion KRW | 61.31% |
| 2007 Q3 | 27.29 Billion KRW | 4.2% |
| 2007 Q1 | 19.67 Billion KRW | 0.0% |
| 2007 Q2 | 26.19 Billion KRW | 33.1% |
| 2007 FY | 26.04 Billion KRW | 0.0% |
| 2007 Q4 | 26.04 Billion KRW | -4.57% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 96.725% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 99.813% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 99.662% |
| HANDOK Inc. | 300.01 Billion KRW | 99.57% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | 95.791% |
| Yuhan Corporation | 230.07 Billion KRW | 99.439% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 99.683% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -116.719% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 99.775% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 98.485% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | 97.018% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 98.574% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | 95.136% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 96.725% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -441.952% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 99.427% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 99.287% |
| JW Holdings Corporation | 554.58 Billion KRW | 99.767% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 99.408% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 99.413% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.242% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 97.204% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | 96.708% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 99.266% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | 98.481% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | 96.725% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 99.452% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 99.725% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.242% |
| Yuhan Corporation | 230.07 Billion KRW | 99.439% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 99.254% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | 98.07% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 99.724% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 99.242% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 98.912% |
| Korea United Pharm Inc. | 40.33 Billion KRW | 96.801% |
| CKD Bio Corp. | 146.92 Billion KRW | 99.122% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 99.116% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | 97.326% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -104.189% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | 97.204% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 99.724% |
| Boryung Corporation | 204.21 Billion KRW | 99.368% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | 98.374% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 98.485% |
| JW Lifescience Corporation | 46.31 Billion KRW | 97.213% |